A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors

被引：0
|
作者：
Schwartz, G. K.
Robertson, S.
Shen, A.
Wang, E.
Pace, L.
Dials, H.
Mendelson, D.
Shannon, P.
Gordon, M.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Exelixis Inc, San Francisco, CA USA
[3] Premier Oncol, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3513
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
    Dickson, Mark A.
    Gordon, Michael S.
    Edelman, Gerald
    Bendell, Johanna C.
    Kudchadkar, Ragini R.
    LoRusso, Patricia M.
    Johnston, Stuart H.
    Clary, Douglas O.
    Schwartz, Gary K.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 349 - 356
  • [2] Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
    Mark A. Dickson
    Michael S. Gordon
    Gerald Edelman
    Johanna C. Bendell
    Ragini R. Kudchadkar
    Patricia M. LoRusso
    Stuart H. Johnston
    Douglas O. Clary
    Gary K. Schwartz
    Investigational New Drugs, 2015, 33 : 349 - 356
  • [3] A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors
    Schwartz, G. K.
    Yazji, S.
    Mendelson, D. S.
    Dickson, M. A.
    Johnston, S. H.
    Wang, E. W.
    Shannon, P.
    Pace, L.
    Gordon, M. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 120 - 120
  • [4] A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs).
    Eder, J. P.
    Appleman, L.
    Heath, E.
    Malburg, L.
    Zhu, A.
    Pilat, M. J.
    Shapiro, G.
    Lorusso, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 131S - 131S
  • [5] Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors
    Siu, L. L.
    Carducci, M.
    Chen, E. X.
    Maclean, M.
    Pili, R.
    King, S.
    Patterson, T.
    Li, Z.
    Kalita, A.
    Reid, G. K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 94 - 95
  • [6] Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
    Rasco, D. W.
    Middleton, M. R.
    Gonzalez, R.
    Corrie, P.
    Pavlick, A.
    Lorigan, P.
    Plummer, R.
    Gore, M.
    Herbert, C.
    Agarwala, S. S.
    Logan, T. F.
    Khleif, S. N.
    Papadopoulos, K. P.
    Rangachari, L.
    Suri, A.
    Xu, Q.
    Kneissl, M.
    Bozon, V.
    Olszanski, A. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S53 - S54
  • [7] MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study
    Rasco, Drew Warren
    Olszanski, Anthony J.
    Patnaik, Amita
    Espino, Guillermo
    Neuwirth, Rachel
    Faucette, Stephanie
    Bargfrede, Michael
    Gangolli, Esha A.
    Walker, Russell M.
    Kneissl, Michelle
    Bozon, Viviana
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A phase I study of oral darinaparsin in patients (pts) with advanced solid tumors (AST).
    Camacho, Luis H.
    Senzer, Neil N.
    Harb, Wael A.
    Barrett, John A.
    Korth, Christopher Charles
    Astl, Dorothea
    Jac, Jaroslaw
    Youssoufian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Phase I study of oral selective c-Met inhibitor EMD 1214063 in pts with advanced solid tumors.
    Falchook, Gerald Steven
    Hong, David S.
    Amin, Hesham M.
    Fu, Siqing
    Piha-Paul, Sarina Anne
    Janku, Filip
    Subbiah, Vivek
    Naing, Aung
    Wheler, Jennifer J.
    Klevesath, Manfred B.
    Koehler, Karola
    Johne, Andreas
    Bladt, Friedhelm
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors
    Kelly, W.
    Petrylak, D.
    Blumenschein, G.
    Lassen, U.
    Jensen, P. Buhl
    DeBono, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 127 - 127
12345